Likewise, in 2003, a study by a Finnish group included 852 stage I patients–36.7% of these T1ab–demonstrating a relative risk of 2.6 in DDFS at nine years for HER-2+ tumours when compared with HER-2- tumours (89% versus 73%, CI 95% 1.1–6.2; p < 0.01) [21]. Here, ERBB2 is linked to neoplasm.